vimarsana.com

Josefin Beate Holz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity CAMBRIDGE, England, May

United statesSan antonioUnited kingdomJustin moserJordi rodon ahnertKyriakos papadopoulosJosefin beate holzHonorhealth research instituteAmerican society of clinical oncologyTherapeutics ltdStorm therapeutics ltdIp groupUtokyo innovation platform co ltdFast track initiativeJustin moser at honorhealth research instituteSeroba life sciences

STORM Therapeutics publishes data in Cancer Discovery showing induction of anti-tumour immunity by METTL3 inhibition

/PRNewswire/ STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies.

United kingdomOliver rauschMark dawsonJerry mcmahonAndrewa guirguisPeter macJosefin beate holzPeter maccallum cancer centreTherapeutics ltdUtokyo innovation platform co ltdTaiho venturesCambridge innovation capitalFast track initiativeIp groupSeroba life sciencesProfessor mark dawson

First patient dosed with novel RNA modifying enzyme inhibitor

A Phase I trial for solid tumours has begun to assess STC-15, the first RNA methyltransferase modifying enzyme inhibitor.

United kingdomTony kouzaridesJerry mcmahonJosefin beate holzUniversity of cambridgeMilner therapeutics instituteStorm therapeutics

Storm doses first patient with solid tumour drug candidate

Candidate is first molecule targeting an RNA methyltransferase enzyme to enter development - News - PharmaTimes

Jerry mcmahonJosefin beate holzBeate holzSolid tumour

STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study

/PRNewswire/ STORM Therapeutics Ltd. (STORM), the biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying.

United kingdomJerry mcmahonJosefin beate holzJustin moserTherapeutics ltdTaiho venturesClinical investigator of honorhealth research instituteMerck kgaIp groupMerck kgaaFast track initiativeCambridge innovation capitalUniversity of tokyo innovation platformHonorhealth research instituteSeroba life sciencesBeate holz

vimarsana © 2020. All Rights Reserved.